top of page
Companies in the News
Sep 14, 2023
Generate:Biomedicines Announces Close of $273M Series C Financing
Funding will advance pipeline of 17 existing programs and approximately 10 new starts annually Company has raised nearly $700 million in...
Jun 20, 2023
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc....
May 22, 2023
EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results
Data Presented at Late-Breaking Session at Heart Rhythm Society 2023: Paves Way for Premarket Approval Application for Federal Drug...
Apr 27, 2023
Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement
Multi-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways...
Apr 13, 2023
Sana Biotechnology Announces Preclinical Data Published in Nature Communications
Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic...
Mar 10, 2023
Ring Therapeutics Raises $86.5M in Series C Funding to Create Next Generation Programmable Medicines
Ring raised a total of $86.5 million from new and returning investors, validating its unique approach to creating next-generation...
Feb 16, 2023
Aera Therapeutics Launches with $193 M for the Next Generation of Transformative Genetic Medicines
Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range...
Jan 9, 2023
Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms
RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human...
Jan 6, 2023
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated...
bottom of page